Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes

被引:7
作者
Eng, Heather [1 ]
Sharma, Raman [1 ]
Wolford, Angela [1 ]
Di, Li [1 ]
Ruggeri, Roger B. [4 ]
Buckbinder, Leonard [5 ]
Conn, Edward L. [4 ]
Dalvie, Deepak K. [2 ]
Kalgutkar, Amit S. [3 ]
机构
[1] Pfizer Inc, Pharmacokinet Pharmacodynam & Metab Dept, Groton, CT 06340 USA
[2] Pfizer Inc, Pharmacokinet Pharmacodynam & Metab Dept, La Jolla, CA USA
[3] Pfizer Inc, Pharmacokinet Pharmacodynam & Metab Dept, Cambridge, MA USA
[4] Pfizer Inc, Worldwide Med Chem, Cambridge, MA USA
[5] Pfizer Inc, Cardiovasc & Metab Res Unit, Cambridge, MA USA
关键词
GLUTATHIONE-DEPLETED MICE; RAT-LIVER; CHEMICAL METABOLISM; STRUCTURE-TOXICITY; S-OXYGENATION; EXPRESSION; DRUG; MECHANISM; PROPYLTHIOURACIL; CYTOCHROME-P450;
D O I
10.1124/dmd.116.070185
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
N1-Substituted-6-arylthiouracils, represented by compound 1 [6-(2,4-dimethoxyphenyl)-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin4(1H)-one], are a novel class of selective irreversible inhibitors of human myeloperoxidase. The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo-[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t(1/2) [half-life = mean +/- S. D.] = 8.6 +/- 0.4 minutes) and dog liver microsomes (t(1/2) = 11.2 +/- 0.4 minutes), but not in human liver microsomes (t(1/2) > 120 minutes). The in vitro metabolic instability also manifested in moderate-to-high plasma clearances of the parent compound in rats and dogs with significant concentrations of M1 detected in circulation. Mild heat deactivation of liver microsomes or coincubation with the flavin-containing monooxygenase (FMO) inhibitor imipramine significantly diminished M1 formation. In contrast, oxidative metabolism of compound 1 to M1 was not inhibited by the pan cytochrome P450 inactivator 1-aminobenzotriazole. Incubations with recombinant FMO isoforms (FMO1, FMO3, and FMO5) revealed that FMO1 principally catalyzed the conversion of compound 1 to M1. FMO1 is not expressed in adult human liver, which rationalizes the species difference in oxidative desulfurization. Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 mM, 20.4 nmol/min/mg protein, and 82.7 ml/min/mg protein, respectively. Addition of excess glutathione essentially eliminated the conversion of compound 1 to M1 in NADPH-supplemented rat and dog liver microsomes, which suggests that the initial FMO1-mediated S-oxygenation of compound 1 yields a sulfenic acid intermediate capable of redox cycling to the parent compound in a glutathione-dependent fashion or undergoing further oxidation to a more electrophilic sulfinic acid species that is trapped intramolecularly by the pendant alcohol motif in compound 1.
引用
收藏
页码:1262 / 1269
页数:8
相关论文
共 58 条
[1]   In Vitro and In Vivo Mechanistic Studies toward Understanding the Role of 1-Aminobenzotriazole in Rat Drug-Drug Interactions [J].
Boily, Marc-Olivier ;
Chauret, Nathalie ;
Laterreur, Julie ;
Leblond, Francois A. ;
Boudreau, Chantal ;
Duquet, Marie-Claude ;
Levesque, Jean-Francois ;
Ste-Marie, Line ;
Pichette, Vincent .
DRUG METABOLISM AND DISPOSITION, 2015, 43 (12) :1960-1965
[2]   MONOOXYGEN DONATION POTENTIAL OF 4A-HYDROPEROXYFLAVINS AS COMPARED WITH THOSE OF A PERCARBOXYLIC ACID AND OTHER HYDROPEROXIDES - MONOOXYGEN DONATION TO OLEFIN, TERTIARY AMINE, ALKYL SULFIDE, AND IODIDE-ION [J].
BRUICE, TC ;
NOAR, JB ;
BALL, SS ;
VENKATARAM, UV .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1983, 105 (08) :2452-2463
[3]   The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens [J].
Caldwell, GW ;
Ritchie, DM ;
Masucci, JA ;
Hageman, W ;
Cotto, C ;
Hall, J ;
Hasting, B ;
Jones, W .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2005, 30 (1-2) :75-83
[4]   STRUCTURAL AND CATALYTIC PROPERTIES OF THE MAMMALIAN FLAVIN-CONTAINING MONOOXYGENASE [J].
CASHMAN, JR .
CHEMICAL RESEARCH IN TOXICOLOGY, 1995, 8 (02) :165-181
[5]   ROLE OF HEPATIC FLAVIN-CONTAINING MONOOXYGENASE-3 IN DRUG AND CHEMICAL METABOLISM IN ADULT HUMANS [J].
CASHMAN, JR ;
PARK, SB ;
BERKMAN, CE ;
CASHMAN, LE .
CHEMICO-BIOLOGICAL INTERACTIONS, 1995, 96 (01) :33-46
[6]   Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny [J].
Chen, Yao ;
Zane, Nicole R. ;
Thakker, Dhiren R. ;
Wang, Michael Zhuo .
DRUG METABOLISM AND DISPOSITION, 2016, 44 (07) :975-983
[7]   Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5 [J].
Cherrington, NJ ;
Cao, Y ;
Cherrington, JW ;
Rose, RL ;
Hodgson, E .
XENOBIOTICA, 1998, 28 (07) :673-682
[8]   Drug therapy: Antithyroid drugs [J].
Cooper, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) :905-917
[9]   COVALENT BINDING OF C-14-LABELED AND S-35 LABELED THIOCARBAMIDES IN RAT HEPATIC MICROSOMES [J].
DECKER, CJ ;
DOERGE, DR .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (04) :881-888
[10]   SPECTROPHOTOMETRIC ASSAY OF THE FLAVIN-CONTAINING MONOOXYGENASE AND CHANGES IN ITS ACTIVITY IN FEMALE MOUSE-LIVER WITH NUTRITIONAL AND DIURNAL CONDITIONS [J].
DIXIT, A ;
ROCHE, TE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1984, 233 (01) :50-63